---
schema_version: "secwatch.filing_event.v1"
accession: "0001618835-23-000014"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:05:36.071006+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Evofem Biosciences CFO Justin J. File resigns; Albert Altro appointed interim CFO

## Summary
- Justin J. File resigned as CFO effective April 3, 2023, to pursue other opportunities; no disagreement with company.
- Albert Altro, with over 30 years of financial experience, appointed interim CFO on March 6, 2023.
- Altro compensated at $275-$450/hour via engagement with his firm Traverse LLC; $40,000 retainer paid.
- Company issued a press release on March 9, 2023, announcing the changes.

## SEC filing metadata
- accession: 0001618835-23-000014
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000161883523000014/0001618835-23-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000161883523000014/evfm-20230303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001618835-23-000014
- JSON: https://secwatch.observer/filing/0001618835-23-000014.json
- Plain text: https://secwatch.observer/filing/0001618835-23-000014.txt

## Key facts
- Executive change
  Justin J. File resigned as Chief Financial Officer at Evofem Biosciences, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On March 3, 2023, Justin J. File provided his notice of resignation from his role as Chief Financial Officer of Evofem Biosciences, Inc., a Delaware corporation (the “Company”), to pursue other opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000161883523000014/0001618835-23-000014-index.htm
- Executive change
  Albert Altro was appointed as Chief Financial Officer at Evofem Biosciences, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On March 6, 2023, Albert Altro was appointed as the interim Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000161883523000014/0001618835-23-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.